Impact of Armodafinil on Cognition in Multiple Sclerosis: A Randomized, Double-blind Crossover Pilot Study

Cognitive and Behavioral Neurology, 09/28/2012

Examine the efficacy of armodafinil in improving cognition in patients with multiple sclerosis (MS). Results provide preliminary evidence that armodafinil may improve delayed verbal recall in patients with multiple sclerosis (MS). A larger trial showing enhanced memory among patients taking long–term armodafinil could serve as a foundation for its possible clinical use as a memory enhancer in patients with MS.


  • The authors conducted a double–blind, placebo–controlled, crossover study testing the efficacy of armodafinil in reducing cognitive problems in patients with MS.
  • They randomized 17 patients to receive a dose of lactose placebo about 2 hours before they underwent a neuropsychological testing session.
  • After a week–long washout period, they gave them a single 250–mg dose of armodafinil about 2 hours before testing them a second time.
  • They randomized another 16 patients to receive the active drug first, then the placebo.
  • They excluded 3 of the participants before analyzing the data.


  • After correcting for multiple comparisons of the 8 neuropsychological dependent measures, they found that the patients had significantly improved delayed memory on a list–learning task after they took armodafinil (P=0.0005), but no improvement on measures of executive function, visual memory, processing speed, or self–reported fatigue.

Print Article Summary Cat 2 CME Report